Skip to main content
Micro-Tech (Nanjing) Co.,Ltd logo

Micro-Tech (Nanjing) Co.,Ltd — Investor Relations & Filings

Ticker · 688029 ISIN · CNE100003MG1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2021-04-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688029

About Micro-Tech (Nanjing) Co.,Ltd

https://www.micro-tech.com.cn/

Micro-Tech (Nanjing) Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical devices. The company focuses on providing advanced solutions for gastroenterology, respiratory medicine, and orthopedics. Its product portfolio includes a wide range of endoscopic diagnostic and therapeutic tools such as biopsy forceps, disposable hemoclips, biliary and esophageal stents, and specialized instruments for Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Micro-Tech emphasizes innovation and quality, maintaining international certifications to serve a global healthcare market. By integrating precision engineering with clinical needs, the company aims to improve patient outcomes and procedural efficiency for medical professionals worldwide.

Recent filings

Filing Released Lang Actions
南微医学科技股份有限公司第二届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 23rd meeting of the second board of directors of 南微医学科技股份有限公司. It includes approvals of various reports such as the 2020 annual board work report, audit committee report, financial statements, profit distribution plan, internal control evaluation report, and other governance and operational matters. The document also references that these reports will be submitted to the 2020 annual shareholders meeting for approval and provides links to the full reports on the Shanghai Stock Exchange website. The document is not the reports themselves but a formal announcement of board meeting decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is under 5,000 characters and is an announcement rather than a full report, so it is not an Annual Report (10-K) or Interim Report (IR).
2021-04-19 Chinese
南微医学科技股份有限公司关于调整募集资金投资项目内部投资结构、实施进度、实施地点及实施主体的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding adjustments to the internal investment structure, implementation progress, locations, and implementing entities of projects funded by raised capital. It discusses the use of proceeds from an IPO, project progress updates, changes in project plans, and approvals from the board and independent directors. The document references regulatory approvals and compliance with listing rules but does not contain financial statements or quarterly/yearly financial results. It is an update on capital use and project progress related to fundraising activities, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8013 characters) and content support this classification with high confidence.
2021-04-19 Chinese
南微医学科技股份有限公司关于以超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of over-raised funds to permanently supplement working capital. It includes details about board and supervisory meetings, independent director opinions, and regulatory compliance. The document does not contain financial statements or detailed financial performance data but rather focuses on the company's capital usage decision and related approvals. The length is about 3,224 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of a Capital/Financing Update (CAP), as it concerns the company's financing activities and capital structure changes related to the use of raised funds.
2021-04-19 Chinese
独立董事对公司对外担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion from the independent directors of the company regarding the external guarantees for the year 2020. It references regulatory notices from the China Securities Regulatory Commission about external guarantees and states that no external guarantees occurred during the reporting period. The document is signed by independent directors and dated April 19, 2021. The content is a formal attestation or certification by officers (independent directors) about compliance with regulations on external guarantees, rather than a full financial report or audit. The document length is short (480 characters), and it serves as a regulatory compliance statement. Therefore, it fits best under Regulatory Filings (RNS) as an official regulatory attestation rather than an audit report or annual report.
2021-04-19 Chinese
南微医学科技股份有限公司关于召开2020年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2020 Annual General Meeting (AGM) of the company 南微医学科技股份有限公司. It includes details such as the date, voting methods, meeting agenda, and instructions for shareholders to attend and vote. It does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is 3267 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2021-04-19 Chinese
南微医学科技股份有限公司2021年度第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2021. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited quarterly financial statements and management explanations of financial performance and changes. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2021
2021-04-19 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.